Lack of effect of ustekinumab in treatment of allergic contact dermatitis

Nannie Bangsgaard; Claus Zachariae; Torkil Menné; Lone Skov

doi:10.1111/j.1600-0536.2011.01907.x

Lack of effect of ustekinumab in treatment of allergic contact dermatitis

Nannie Bangsgaard, Claus Zachariae, Torkil Menné, Lone Skov

9 Citations (Scopus)

Abstract

Background. Allergic contact dermatitis is a chronic inflammatory T cell mediated disease that can be recalcitrant to existing treatments. Ustekinumab is a monocloncal antibody blocking IL-12 and IL-23, shown to be effective and safe for patients with psoriasis. Despite both IL-12 and IL-23 involvement in contact allergy, the effect of Ustekinumab on allergic contact dermatitis has not been reported. Objectives. To evaluate the clinical effect of Ustekinumab in patients with allergic contact dermatitis. Methods. A retrospective, case cohort study of patients with allergic contact dermatitis treated with Ustekinumab in our department. Results. Five patients had been treated with Ustekinumab for allergic contact dermatitis, with limited effect. Conclusion. Our observation suggests that, although theoretically plausible, Ustekinumab does not seem to be a valuable therapeutic approach for chronic allergic contact dermatitis.

Original language	English
Journal	Contact Dermatitis
Volume	65
Issue number	4
Pages (from-to)	227-30
Number of pages	4
ISSN	0105-1873
DOIs	https://doi.org/10.1111/j.1600-0536.2011.01907.x
Publication status	Published - 1 Oct 2011

Access to Document

10.1111/j.1600-0536.2011.01907.x

Cite this

@article{35b5939ab4344ff4a2c35267ed7e7c96,

title = "Lack of effect of ustekinumab in treatment of allergic contact dermatitis",

abstract = "Background. Allergic contact dermatitis is a chronic inflammatory T cell mediated disease that can be recalcitrant to existing treatments. Ustekinumab is a monocloncal antibody blocking IL-12 and IL-23, shown to be effective and safe for patients with psoriasis. Despite both IL-12 and IL-23 involvement in contact allergy, the effect of Ustekinumab on allergic contact dermatitis has not been reported. Objectives. To evaluate the clinical effect of Ustekinumab in patients with allergic contact dermatitis. Methods. A retrospective, case cohort study of patients with allergic contact dermatitis treated with Ustekinumab in our department. Results. Five patients had been treated with Ustekinumab for allergic contact dermatitis, with limited effect. Conclusion. Our observation suggests that, although theoretically plausible, Ustekinumab does not seem to be a valuable therapeutic approach for chronic allergic contact dermatitis.",

author = "Nannie Bangsgaard and Claus Zachariae and Torkil Menn{\'e} and Lone Skov",

note = "{\textcopyright} 2011 John Wiley & Sons A/S.",

year = "2011",

month = oct,

day = "1",

doi = "10.1111/j.1600-0536.2011.01907.x",

language = "English",

volume = "65",

pages = "227--30",

journal = "Contact Dermatitis",

issn = "0105-1873",

publisher = "Wiley-Blackwell",

number = "4",

}

TY - JOUR

T1 - Lack of effect of ustekinumab in treatment of allergic contact dermatitis

AU - Bangsgaard, Nannie

AU - Zachariae, Claus

AU - Menné, Torkil

AU - Skov, Lone

PY - 2011/10/1

Y1 - 2011/10/1

N2 - Background. Allergic contact dermatitis is a chronic inflammatory T cell mediated disease that can be recalcitrant to existing treatments. Ustekinumab is a monocloncal antibody blocking IL-12 and IL-23, shown to be effective and safe for patients with psoriasis. Despite both IL-12 and IL-23 involvement in contact allergy, the effect of Ustekinumab on allergic contact dermatitis has not been reported. Objectives. To evaluate the clinical effect of Ustekinumab in patients with allergic contact dermatitis. Methods. A retrospective, case cohort study of patients with allergic contact dermatitis treated with Ustekinumab in our department. Results. Five patients had been treated with Ustekinumab for allergic contact dermatitis, with limited effect. Conclusion. Our observation suggests that, although theoretically plausible, Ustekinumab does not seem to be a valuable therapeutic approach for chronic allergic contact dermatitis.

AB - Background. Allergic contact dermatitis is a chronic inflammatory T cell mediated disease that can be recalcitrant to existing treatments. Ustekinumab is a monocloncal antibody blocking IL-12 and IL-23, shown to be effective and safe for patients with psoriasis. Despite both IL-12 and IL-23 involvement in contact allergy, the effect of Ustekinumab on allergic contact dermatitis has not been reported. Objectives. To evaluate the clinical effect of Ustekinumab in patients with allergic contact dermatitis. Methods. A retrospective, case cohort study of patients with allergic contact dermatitis treated with Ustekinumab in our department. Results. Five patients had been treated with Ustekinumab for allergic contact dermatitis, with limited effect. Conclusion. Our observation suggests that, although theoretically plausible, Ustekinumab does not seem to be a valuable therapeutic approach for chronic allergic contact dermatitis.

U2 - 10.1111/j.1600-0536.2011.01907.x

DO - 10.1111/j.1600-0536.2011.01907.x

M3 - Journal article

SN - 0105-1873

VL - 65

SP - 227

EP - 230

JO - Contact Dermatitis

JF - Contact Dermatitis

IS - 4

ER -

Lack of effect of ustekinumab in treatment of allergic contact dermatitis

Abstract

Access to Document

Fingerprint

Cite this